Journal of Autism and Developmental Disorders

, Volume 39, Issue 12, pp 1629–1635

Open-Label Memantine in Fragile X Syndrome

  • Craig A. Erickson
  • Jennifer E. Mullett
  • Christopher J. McDougle
Original Paper

Abstract

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.

Keywords

Memantine Fragile X syndrome Inattention Hyperactivity Social withdrawal Irritability 

References

  1. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.Google Scholar
  2. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (text revision) (4th ed.). Washington, D.C.: American Psychiatric Association.CrossRefGoogle Scholar
  3. Bailey, D. B., Jr., Hatton, D. D., Skinner, M., & Mesibov, G. (2001). Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. Journal of Autism and Developmental Disorders, 31(2), 165–174.CrossRefPubMedGoogle Scholar
  4. Bassell, G. J., & Gross, C. (2008). Reducing glutamate signaling pays off in fragile X. Nature Medicine, 14(3), 249–250.CrossRefPubMedGoogle Scholar
  5. Bear, M. F. (2005). Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes, Brain, and Behavior, 4(6), 393–398.CrossRefPubMedGoogle Scholar
  6. Bear, M. F., Dolen, G., Osterweil, E., & Nagarajan, N. (2008). Fragile X: Translation in action. Neuropsychopharmacology, 33(1), 84–87.CrossRefPubMedGoogle Scholar
  7. Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27(7), 370–377.CrossRefPubMedGoogle Scholar
  8. Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics, 46(4), 266–271.CrossRefPubMedGoogle Scholar
  9. Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., et al. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial. Journal of Child and Adolescent Psychopharmacology, 16(5), 525–540.CrossRefPubMedGoogle Scholar
  10. Berry-Kravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndrome—present and future. Mental Retardation and Developmental Disabilities Research Reviews, 10(1), 42–48.CrossRefPubMedGoogle Scholar
  11. Chez, M. G., Aimonovitch, M., Buchanan, T., Mrazek, S., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19(3), 165–169.PubMedGoogle Scholar
  12. Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579.CrossRefPubMedGoogle Scholar
  13. Clifford, S., Dissanayake, C., Bui, Q. M., Huggins, R., Taylor, A. K., & Loesch, D. Z. (2007). Autism spectrum phenotype in males and females with fragile X full mutation and premutation. Journal of Autism and Developmental Disorders, 37(4), 738–747.CrossRefPubMedGoogle Scholar
  14. Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33(4), 427–433.CrossRefPubMedGoogle Scholar
  15. Dolen, G., & Bear, M. F. (2005). Courting a cure for fragile X. Neuron, 45(5), 642–644.CrossRefPubMedGoogle Scholar
  16. Dolen, G., & Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. Journal of Physiology, 586(6), 1503–1508.CrossRefPubMedGoogle Scholar
  17. DuPaul, G., Power, T., Anastopaulus, A., & Reid, R. (1998). ADHD rating scale IV: Checklists, norms, and clinical interpretation. New York: Guilford.Google Scholar
  18. Erickson, C. A., & Chambers, J. E. (2006). Memantine for disruptive behavior in autistic disorder. Journal of Clinical Psychiatry, 67(6), 1000.PubMedCrossRefGoogle Scholar
  19. Erickson, C. A., Posey, D. J., Stigler, K. A., Mullett, J., Katschke, A. R., & McDougle, C. J. (2007). A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl), 191(1), 141–147.CrossRefGoogle Scholar
  20. Evans, S. M., Levin, F. R., Brooks, D. J., & Garawi, F. (2007). A pilot double-blind treatment trial of memantine for alcohol dependence. Alcoholism, Clinical and Experimental Research, 31(5), 775–782.CrossRefPubMedGoogle Scholar
  21. Findling, R. L., McNamara, N. K., Stansbrey, R. J., Maxhimer, R., Periclou, A., Mann, A., et al. (2007). A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Journal of Child and Adolescent Psychopharmacology, 17(1), 19–33.CrossRefPubMedGoogle Scholar
  22. Florencia, G., Irene, S., & Veronica, F. (2006). Fragile-X mental retardation: Molecular diagnosis in Argentine patients. Journal of Biochemistry and Molecular Biology, 39(6), 766–773.PubMedGoogle Scholar
  23. Gerard, B., Le Heuzey, M. F., Brunie, G., Lewine, P., Saiag, M. C., Cacheux, V., et al. (1997). Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children. Annales de Genetique, 40(3), 139–144.PubMedGoogle Scholar
  24. Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76–338. Rockville, MD: U.S. DHEW, NIMH.Google Scholar
  25. Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7746–7750.CrossRefPubMedGoogle Scholar
  26. Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., et al. (2008). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology, 34(5), 1322–1329.CrossRefPubMedGoogle Scholar
  27. Lord, C., Rutter, M., Goode, S., Heemsbergen, J., Jordan, H., Mawhood, L., et al. (1989). Autism diagnostic observation schedule: A standardized observation of communicative and social behavior. Journal of Autism and Developmental Disorders, 19(2), 185–212.CrossRefPubMedGoogle Scholar
  28. Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24(5), 659–685.CrossRefPubMedGoogle Scholar
  29. Mobius, H. J., Stoffler, A., & Graham, S. M. (2004). Memantine hydrochloride: Pharmacological and clinical profile. Drugs Today (Barcelona), 40(8), 685–695.CrossRefGoogle Scholar
  30. Muhonen, L. H., Lonnqvist, J., Juva, K., & Alho, H. (2008). Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. Journal of Clinical Psychiatry, 69(3), 392–399.CrossRefPubMedGoogle Scholar
  31. Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., et al. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517–524.CrossRefPubMedGoogle Scholar
  32. Parsons, C. G., & Gilling, K. (2007). Memantine as an example of a fast, voltage-dependent, open channel N-methyl-d-aspartate receptor blocker. Methods in Molecular Biology, 403, 15–36.CrossRefPubMedGoogle Scholar
  33. Pilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., et al. (2008). Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of FMR1 KO mice. The Journal of Physiology, 587(Pt 4), 787–804.CrossRefPubMedGoogle Scholar
  34. Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Mobius, H. J. (2003). Memantine in moderate-to-severe Alzheimer’s disease. New England Journal of Medicine, 348(14), 1333–1341.CrossRefPubMedGoogle Scholar
  35. Rogers, S. J., Wehner, D. E., & Hagerman, R. (2001). The behavioral phenotype in fragile X: Symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. Journal of Developmental and Behavioral Pediatrics, 22(6), 409–417.PubMedGoogle Scholar
  36. SPSS Inc. (2005). SPSS 13.0 for windows. Chicago, IL: SPSS, Inc.Google Scholar
  37. Tervonen, T. A., Louhivuori, V., Sun, X., Hokkanen, M. E., Kratochwil, C. F., Zebryk, P., et al. (2008). Aberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome. Neurobiology of Disease, 33(2), 250–259.CrossRefPubMedGoogle Scholar
  38. Zarate, C. A., Jr., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., et al. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry, 163(1), 153–155.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Craig A. Erickson
    • 1
    • 2
  • Jennifer E. Mullett
    • 1
    • 2
  • Christopher J. McDougle
    • 1
    • 2
  1. 1.Department of PsychiatryIndiana University School of MedicineIndianapolisUSA
  2. 2.Christian Sarkine Autism Treatment CenterJames Whitcomb Riley Hospital for ChildrenIndianapolisUSA

Personalised recommendations